Donguibogam Evidence Bridge한국어

Coptis 黃連

Pharmaceutical nameCoptidis Rhizoma

Evidence grade: Insufficientauto-proposed · unreviewedSafety signal: Adverse-event literature existsMapping confidence: Strong correspondence

The three axes are assessed independently and are never combined into a single score.

KTKP records the origin species as Coptis chinensis Franch. It has not yet been cross-checked against the Korean Pharmacopoeia, so the identification confidence is not raised to an official code mapping. The same drug appears under 2 records as name variants. The same source species also yields 1 other separately registered drug(s) (Alcohol cum Coptidis Rhizoma), which must not be conflated. The name most used for this taxon in current literature is Coptis chinensis.

Tradition · what the text describes

탕액편

The sub-section within this volume has not been verified against the original text yet.

The KTKP traditional materia medica record (M0004374) gives the origin species as Coptis chinensis Franch, the part used as 뿌리줄기, and the properties as 고(苦), 무독(無毒), 한(寒). It lists 간(肝), 대장(大腸), 심(心), 위(胃) as the channels entered. The same record cites the Donguibogam (1613) as the source for its indications.

Properties & channel entry: 고(苦), 무독(無毒), 한(寒) · 간(肝), 대장(大腸), 심(心), 위(胃)

Source species: Coptis chinensis Franch (뿌리줄기)

Read the original: Korean Medicine Classics DB ↗

Modern · documented evidence

Alzheimer Diseaseevidence for this indication

Evidence grade: Insufficientauto-proposed · unreviewed
  • 2 registered trial(s) exist but no published systematic review or RCT was found. Check whether the research is ongoing or simply unpublished.
  • The indication was derived automatically from the Condition field of 2 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.

Literature

SR 0 · RCT 0 · preclinical 0

No human studies were found within the sources searched. This means "not yet studied", not "does not work".

Query used

We publish the exact query behind these counts so you can reproduce them yourself.

SRC:MED AND ((TITLE_ABS:"Coptis chinensis")) AND TITLE_ABS:"Alzheimer Disease"

    Clinical trials

    Chronic Insomniaevidence for this indication

    Evidence grade: Insufficientauto-proposed · unreviewed
    • 2 registered trial(s) exist but no published systematic review or RCT was found. Check whether the research is ongoing or simply unpublished.
    • The indication was derived automatically from the Condition field of 2 registered trial(s). It reflects what is currently being studied, not a traditional use, and a curator should confirm the label is apt.

    Literature

    SR 0 · RCT 0 · preclinical 0

    No human studies were found within the sources searched. This means "not yet studied", not "does not work".

    Query used

    We publish the exact query behind these counts so you can reproduce them yourself.

    SRC:MED AND ((TITLE_ABS:"Coptis chinensis")) AND TITLE_ABS:"Chronic Insomnia"

      Clinical trials

      Safety

      auto-proposed · unreviewed

      • 17 adverse-event or toxicity record(s) were found. This only flags that literature exists — read the abstracts to decide between "caution" and "harm confirmed".
      • 2 interaction-related record(s) are retrievable. This flags that literature exists — it is not an interaction checker (§3.4).
      • The KTKP record states the following traditional contraindication: 고한(苦寒)으로 상위(傷胃)시키므로 비위(脾胃)가 허한(虛寒)하고 실화(實火)가 있지 않으면 응용하여서는 안된다. 즉 위한구토(胃寒嘔吐)와 비허설사(脾虛泄瀉)의 증(證)에는 복용을 기(忌)하고, 과양(過量)이나 구복(久服)은 마땅하지 않다.

      Adverse-event and toxicity literature

      This is not a finding of harm — it lists literature that is retrievable. Read the papers to decide.

      Interaction literature

      This lists literature that is retrievable — it is not a judgement that an interaction exists. Read the papers to decide.

      Sources